SOPHiA GENETICS (SOPH) Stock Forecast & Price Target
$669.71M
Market Cap
-6.39
P/E
786.71
Forward P/E
—
Score
SOPH price $7.87 -0.00 -0.04%
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 25362000 | 28400000 | 40450000 | 47560000 | 62371000 | 65173000 | 77271000 |
SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals…
Consensus Buy from 8 analysts. Average price target $11.50, +46.2% versus the current price. Low $9.00. High $14.00.
Insights · Dividends · Forecast · Financials · Learn
Analysts have an average 12-month price target of $11.50 for SOPHiA GENETICS (SOPH), 46.2% above the current price of $7.87. Of 8 analysts covering the stock, 7 rate it Buy or Strong Buy, 1 Hold, and 0 Sell or Strong Sell, giving a consensus of Buy.
Forecasts are third-party estimates and often wrong. They are not investment advice.
| Low | $9.00 |
|---|---|
| Average | $11.50 |
| High | $14.00 |
The average is 46.2% above the current price of $7.87.
Of 8 analysts, 7 rate SOPHiA GENETICS Buy or Strong Buy, 1 Hold, and 0 Sell or Strong Sell. The consensus label is Buy. That split is not a recommendation.
Analyst averages on file: 2026, EPS -0.94, revenue $95.25 million. 2027, EPS -0.63, revenue $117.89 million.
The Stocklytics Score, when it is published for SOPH, averages value, quality, and growth on a 0–100 scale. It is not a price target. Fair value is a separate estimate on the fair value tab.
$11.50 average, with a published range of $9.00 to $14.00.
The consensus is Buy from 8 analysts. This is not a recommendation.
Analysts' average EPS estimate for 2026 on file is -0.94. The average revenue estimate is $95.25 million.
No reliable forecast exists that far out.
The next earnings date is shown on the stock page when a future report is on the calendar. This forecast does not invent a date.
Related: SOPHiA GENETICS · Financials · Dividends · Compare · AI stocks
Capital is at risk. Stocklytics is operated by Stocklytics Inc., a Marshall Islands company. It is not regulated by the FCA and does not give investment advice.
$669.71M
Market Cap
-6.39
P/E
786.71
Forward P/E
—
Score